Developers partner on cemsidomide plus Elrexfio to treat myeloma
C4 Therapeutics and Pfizer are teaming up to evaluate whether combining C4’s investigational oral therapy cemsidomide with Pfizer’s approved multiple myeloma treatment Elrexfio…
Margarida Maia, PhD, science writer—
Articles by Margarida Maia
Clinical trial testing BPM31510 for glioblastoma now fully enrolled
Enrollment is now complete in a Phase 2b clinical trial testing Bpgbio’s BPM31510, a treatment candidate for glioblastoma multiforme (GBM), a rapidly progressing type…
Rapid spread of rare pancreatic cancer to liver detailed in report
A rapidly growing pancreatic signet ring cell adenocarcinoma, a rare and aggressive type of pancreatic cancer, was reported to have spread to the liver…
Modeyso added to NCCN guidelines for rare brain cancer
The National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to include Modeyso (dordaviprone) as an appropriate option for a rare recurrent…
Novocure files for FDA approval of TTFields for pancreatic cancer
Novocure has filed an application asking the U.S. Food and Drug Administration to approve its Tumor Treating Fields (TTFields) therapy for treating locally advanced…
Stenoparib wins FDA fast track status for advanced ovarian cancer
The U.S. Food and Drug Administration (FDA) has given fast track status to stenoparib, an experimental treatment Allarity Therapeutics has been testing for advanced…
Geneseeq’s new blood test may detect early-stage pancreatic cancer
Geneseeq Technology is developing a blood test that uses cell-free DNA (cfDNA) and artificial intelligence (AI) to detect early-stage pancreatic ductal adenocarcinoma — the…
Europe extends Darzalex approval as multiple myeloma treatment
The European Commission has extended its approval of Johnson & Johnson’s Darzalex (daratumumab) for injection under the skin as part of a quadruple regimen…
Minimal residual disease is potential early outcome measure in myeloma
Minimal residual disease or MRD — defined as a very small number of cancer cells that remain in the body during or after treatment —…
Elraglusib can prolong survival in metastatic pancreatic cancer: Trial
Adding elraglusib, a small molecule being developed by Actuate Therapeutics, to standard chemotherapy with gemcitabine and nab-paclitaxel (GnP) as a first-line treatment for metastatic…
